TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$41.78-0.17%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · TEVA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks TEVA against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Key innovative brands continued to drive Teva’s portfolio transformation , collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency: AUSTEDO glo…
Stated in 3 of 3 supplied quarters. Management reported: “Key innovative brands continued to drive Teva’s portfolio transformation , collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency: AUSTEDO global revenues were $751 million, increasing 21% year-over-year in local currency.” “1 Teva is raising its 2026 revenue outlook for each of these key innovative brands, and now expects combined 2026 revenue of ~$3.7 billion reflecting a ~17% YoY growth at the mid-point.”
“Key innovative brands continued to drive Teva’s portfolio transformation , collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency: AUSTEDO glo…”
“Pivot to Growth Strategy In the second quarter of 2026, we continued to execute on the four key pillars of our “Pivot to Growth” strategy, announced in May 2023: Delivering on our growth engines - Te…”
“Pivot to Growth Strategy In the first quarter of 2026, we continued to execute on the four key pillars of our “Pivot to Growth” strategy, announced in May 2023: Delivering on our growth engines - Tev…”
Focusing our business Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support…
Stated in 3 of 3 supplied quarters. Management reported: “Focusing our business Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including ~two-thirds expected to be realized in 2026.” “Continuing to transform and modernize our business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of achieving a 30% non-GAAP operating income margin by 2027 and approximately $700 million of net savings by 2027.”
Teva’s biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.
Stated in 3 of 3 supplied quarters. Management reported: “Teva’s biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.” “Generics Powerhouse: generics global revenues were lower in Q2 2026 vs. Q2 2025, mainly due to lower revenues from lenalidomide capsules (a generic version of Revlimid ® ) in the U.S.; biosimilars portfolio performed strongly and on track to deliver $800 million in revenues by 2027.”
Innovative pipeline successes strengthen Teva’s longer-term growth profile with the potential to launch at least one product per year over five years: The U.S. FDA accepted the ecopipam New Drug Appl…
Stated in 3 of 3 supplied quarters. Management reported: “Innovative pipeline successes strengthen Teva’s longer-term growth profile with the potential to launch at least one product per year over five years: The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.”
At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile.
Stated in 3 of 3 supplied quarters. Management reported: “At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile.” “Focusing our business - We are actively transforming and modernizing our business through Teva Transformation programs and expect to realize two-thirds of the targeted savings in 2026, while maintaining disciplined capital allocation.”
“At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile.”
Over the trailing year it converted 3.49x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 54% of the time over the next year (vs 44% for the rest of the cohort, n=2525).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“Focusing our business Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support…”
“Continuing to transform and modernize our business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of…”
“Continuing to transform and modernize our business through Teva Transformation programs – combined with innovative product growth, expected to achieve 30% non-GAAP operating income margin by 2027.”
“Teva’s biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.”
“Generics Powerhouse: generics global revenues were lower in Q2 2026 vs. Q2 2025, mainly due to lower revenues from lenalidomide capsules (a generic version of Revlimid ® ) in the U.S.; biosimilars po…”
“Mr. Francis added, “In parallel, biosimilars are becoming an increasingly important growth contributor, alongside new product launches in generics, reinforcing the foundational importance of Teva's g…”
“Innovative pipeline successes strengthen Teva’s longer-term growth profile with the potential to launch at least one product per year over five years: The U.S. FDA accepted the ecopipam New Drug Appl…”
“Innovative late-stage pipeline progressing at speed, addressing high unmet need : ecopipam: the acquisition of Emalex Biosciences (Emalex) and its primary asset, ecopipam (EBS-101), a first-in-class…”
“Stepping up innovation - We continued to advance our innovative late-stage pipeline.”
“Focusing our business - We are actively transforming and modernizing our business through Teva Transformation programs and expect to realize two-thirds of the targeted savings in 2026, while maintain…”
“These results reflect disciplined execution of our Pivot to Growth strategy, and our focus remains unchanged: growing our innovative portfolio, improving margins and advancing key value-unlocking por…”